Detail akcie Labcorp Hldgs online

Business Summary: Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Labcorp Holdings Inc revenues increased 8% to $10.44B. Net income increased 18% to $711.8M. Revenues reflect DX segment increase of 8% to $8.15B, BLS segment increase of 7% to $2.31B. Net income benefited from DX segment income increase of 9% to $1.36B, General corporate segment loss decrease of 14% to $606M, BLS segment income increase of 10% to $362.4M. Dividend per share remained flat at $2.16.